Cold Spring Harbor Laboratory Joins the Illumina Genome Network
News May 28, 2012
Illumina, Inc. has announced that the Cold Spring Harbor Laboratory (CSHL) has joined the Illumina Genome Network (IGN) to provide researchers with broader access to whole genome sequencing (WGS) services.
IGN and CSHL will work in collaboration to bring together CSHL’s expertise in molecular biology and cancer genomics with Illumina’s industry-leading sequencing technology.
“We welcome the distinguished Cold Spring Harbor Laboratory to our prestigious group of IGN partners, and are excited to expand opportunities for deep scientific collaboration,” said Christian Henry, Senior Vice President and General Manager of Illumina’s Genomic Solutions Business.
Henry continued, “Through the Illumina Genome Network, we believe we can speed discovery in areas where CSHL excels, including approaches to understanding tumor development, progression and therapeutic response.”
“The goal of our work at the Cold Spring Harbor Laboratory is to apply our research on basic biological mechanisms to improve the diagnosis and treatment of cancer, as well as neurological disorders and other diseases,” said Richard McCombie, Professor, Cold Spring Harbor Laboratory.
McCombie continued, “By participating in IGN, we are enriching the capabilities of researchers as they strive to solve biology’s most challenging problems.”
IGN links researchers needing large-scale, whole human genome sequencing with world class institutions that provide this service, and delivers unmatched access to the highest quality of whole genome sequencing data.
All IGN partners are experienced and well-published using Illumina TruSeq™ technology, and have completed Illumina’s Certified Service Provider (CSPro) certification.
Each possesses ten or more Illumina sequencing systems (HiSeq 2000 systems and/or Genome Analyzers), providing the scalability to handle large sequencing projects with rapid completion times.
CSHL joins six IGN partners who provide a full range of WGS services:
• The Broad Institute in Cambridge, Massachusetts
• British Columbia Cancer Agency in Vancouver, Canada
• University of Washington Department of Genome Sciences in Seattle, Washington
• National Center for Genome Resources in Santa Fe, New Mexico
• Macrogen & Genomic Medicine Institute in Seoul, Korea
• Illumina’s FastTrack Services lab in San Diego, California
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.